| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 03/31/2004 | EP1401837A1 Purine derivatives as a2b adenosine receptor antagonists |
| 03/31/2004 | EP1401835A1 Carboline derivatives as pde-5 inhibitors |
| 03/31/2004 | EP1401831A1 Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors |
| 03/31/2004 | EP1401823A1 Substituted benzopyran derivatives against arrhythmia |
| 03/31/2004 | EP1401822A1 Naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| 03/31/2004 | EP1401820A1 5-ht receptor ligands and uses thereof |
| 03/31/2004 | EP1401819A1 5-ht receptor ligands and uses thereof |
| 03/31/2004 | EP1401818A2 Targeted multivalent macromolecules |
| 03/31/2004 | EP1401809A1 Tryptase inhibitors |
| 03/31/2004 | EP1401808A2 Gpe analogs and peptidomimetics |
| 03/31/2004 | EP1401506A2 Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy |
| 03/31/2004 | EP1401502A1 Pharmaceutical formulation |
| 03/31/2004 | EP1401485A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3 4-(2- 4-methane sulfonyl oxyphenyl ethoxy)phenyl] propanoic acid or 3- 4- 2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl -(s)-2-ethoxy propanoic acid and insulin |
| 03/31/2004 | EP1401482A1 Yin yang-1 |
| 03/31/2004 | EP1401480A2 Use of endostatin in the treatment of ocular neovascularization |
| 03/31/2004 | EP1401479A2 Detection and therapy of vulnerable plaque with photodynamic compounds |
| 03/31/2004 | EP1401476A2 Igf antagonist peptides |
| 03/31/2004 | EP1401475A2 Prmts as modifiers of the p53 pathway and methods of use |
| 03/31/2004 | EP1401472A2 Alternative splice forms of proteins as basis for multiple therapeutic modalities |
| 03/31/2004 | EP1401470A2 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use |
| 03/31/2004 | EP1401469A2 Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways |
| 03/31/2004 | EP1401468A2 Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases |
| 03/31/2004 | EP1401464A2 Dietetic preparation with hypocholesterolemic activity |
| 03/31/2004 | EP1401461A2 Selective cox-2 inhibition from edible plant extracts |
| 03/31/2004 | EP1401460A2 Selective cox-2 inhibition from plant extracts |
| 03/31/2004 | EP1401455A1 Use of a phosphate adsorbent to combat vascular diseases |
| 03/31/2004 | EP1401451A2 Quinazoline derivatives which promote the release of parathyroid hormone |
| 03/31/2004 | EP1401450A1 New use of a pyridazinone derivative |
| 03/31/2004 | EP1401449A1 Tetracyclic compounds as pde5-inhibitors |
| 03/31/2004 | EP1401447A2 Use of inhibitors of the protease of the human immunodeficiency virus (hiv) to block cell migration and/or invasion, tissue infiltration and oedema for the therapy of diseases associated therewith |
| 03/31/2004 | EP1401446A1 Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen |
| 03/31/2004 | EP1401441A2 Allosteric adenosine receptor modulators |
| 03/31/2004 | EP1401439A1 Use of bicyclo compounds for treating alzheimer's disease |
| 03/31/2004 | EP1401434A1 Modulators of peroxisome proliferator activated receptors (ppar) |
| 03/31/2004 | EP1401433A2 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| 03/31/2004 | EP1401432A2 Imidazole derivatives for modulating sodium channels |
| 03/31/2004 | EP1401431A2 Human growth hormone antagonists |
| 03/31/2004 | EP1401420A2 Perturbed membrane-binding compounds |
| 03/31/2004 | EP1401413A2 Use of tyrosine kinase inhibitions for treating allergic diseases |
| 03/31/2004 | EP1401412A2 Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis |
| 03/31/2004 | EP1401410A2 Immunomodulation and effect on cell processes relating to serotonin family receptors |
| 03/31/2004 | EP1401409A2 Stable powder inhalation dosage formulation |
| 03/31/2004 | EP1401408A1 Controlled heat induced rapid delivery of pharmaceuticals from skin depot |
| 03/31/2004 | EP1401375A2 Methods for inhibiting macrophage colony stimulating factor and c-fms-dependent cell signaling |
| 03/31/2004 | EP1301501B1 Tocotrienolquinone cyclisation product with an anti-hypercholesterol effect |
| 03/31/2004 | EP1250156A4 Method for nucleic acid transfection of cells |
| 03/31/2004 | EP1232174A4 Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| 03/31/2004 | EP1232144B1 Novel il-8 receptor antagonists |
| 03/31/2004 | EP1210072B1 Plastic films, especially for use in a dermal or transdermal therapeutic system |
| 03/31/2004 | EP1181294B1 Novel derivatives and analogues of galanthamin |
| 03/31/2004 | EP1177186B1 Ureas and their use as cell adhesion modulators |
| 03/31/2004 | EP1140139B9 Use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia |
| 03/31/2004 | EP1102766B1 Triazolopyridines for the treatment of thrombosis disorders |
| 03/31/2004 | EP1025098B1 Benzothiophenes |
| 03/31/2004 | EP1015421B1 New phenylamidine derivatives, a process for preparing the same and their use as medicaments |
| 03/31/2004 | EP0996431B1 Synergistic compositions of lycopene and vitamin e for the prevention of ldl oxidation |
| 03/31/2004 | EP0977578B1 Compositions to enhance the cytoprotective effects of polycyclic phenolic compounds through the synergistic interaction with anti-oxidants |
| 03/31/2004 | EP0952835B1 Method of treatment of heart disease caused by chlamydia pneumoniae |
| 03/31/2004 | EP0937030B1 3-amino-propoxyphenyl derivatives (i) |
| 03/31/2004 | EP0901470B1 Indole derivatives useful as endothelin receptor antagonists |
| 03/31/2004 | EP0808316B1 Vasoconstrictive substituted 2,3-dihydro-1,4-dioxinopyridines |
| 03/31/2004 | EP0781766B1 Heterocyclic derivative and medicine |
| 03/31/2004 | EP0735818B1 MACROPHAGE INFLAMMATORY PROTEINS MIP-3, MIP-4 AND MIP-1gamma |
| 03/31/2004 | CN1486368A Methods for the production of multimeric proteins, and related compositions |
| 03/31/2004 | CN1486327A 载脂蛋白类似物 Apolipoprotein analogues |
| 03/31/2004 | CN1486320A Inhibitors of cruzipain and other cysteine proteases |
| 03/31/2004 | CN1486314A Aminotriazolopyridiine derivatives as adenosine receptor ligands |
| 03/31/2004 | CN1486312A Pyrazole compounds useful as protein kinase inhibitors |
| 03/31/2004 | CN1486311A Pyrazole compounds useful as protein kinase inhibitors |
| 03/31/2004 | CN1486310A Pyrazole compounds useful as protein kinase inhibitors |
| 03/31/2004 | CN1486302A Abca-1 elevating compounds against coronary artery disease or atherosclerosis |
| 03/31/2004 | CN1486301A 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| 03/31/2004 | CN1486298A Prodrugs of excitatory amino acids |
| 03/31/2004 | CN1486196A Complex of modafinil and cyclodextrin |
| 03/31/2004 | CN1486190A Compositions containing an active fraction isolated from scutellariae barbatae and methods of use |
| 03/31/2004 | CN1486189A Use of a strain of lactobacillus reducing the risk factors involved in the metabolic syndrome |
| 03/31/2004 | CN1486182A Medicinal compositions |
| 03/31/2004 | CN1486176A Pharmaceutical compositions comprising amlodipine maleate |
| 03/31/2004 | CN1485077A Sapid invigorating yang five-recouping capsule and the preparation thereof |
| 03/31/2004 | CN1485076A A Chinese patent medicines fomula for curing cerebral arteriosclersis and the preparation process thereof |
| 03/31/2004 | CN1485061A Gingko leaf drop pill |
| 03/31/2004 | CN1485053A Medication formulation for premonitory apoplexy and its preparation method |
| 03/31/2004 | CN1485043A Adetphos sodium chloride injection and its preparation method |
| 03/31/2004 | CN1485031A Medication oral liquid |
| 03/31/2004 | CN1143857C Bisethers of 1-oxa, aza and thianaphthalen-2-ones as phospholamban inhibitors |
| 03/31/2004 | CN1143854C Novel 2-(iminomethyl) amino-phenyl derivatives,the preparation thereof, application as medicines and pharmaceutical compositions containing same |
| 03/31/2004 | CN1143848C 2-arylethyl-(piperidin-4-ylmethyl) amine derivatives as muscarinic receptor antagonists |
| 03/31/2004 | CN1143688C Triacetin as transdermal permeation enhancer |
| 03/31/2004 | CN1143684C Medicine for treating hypertension and heart disease and its preparation |
| 03/31/2004 | CN1143674C Refractory vasculitis therapeutic agent |
| 03/30/2004 | US6713650 ABCA-1 elevating compounds |
| 03/30/2004 | US6713635 As chemical intermediates used for the preparation of s-alpha-ethyl-2-oxo-1-pyrrolidine acetamide |
| 03/30/2004 | US6713634 Pyrroloazepine derivatives |
| 03/30/2004 | US6713628 Process for preparing pharmacologically acceptable salt of N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-amino acid |
| 03/30/2004 | US6713621 Chimeric compositions having multi-modalities are also provided which can affect a plurality of gene functions by interfering with splicing or translation as well as transcription |
| 03/30/2004 | US6713604 Synthetic cyclic peptides that inhibit that binding |
| 03/30/2004 | US6713515 Administering benzyl, naphthyl acid derivatives |
| 03/30/2004 | US6713508 Such as 7-(3-(3-trifluoromethyl-7-propyl-6-benz-(4,5)-isoxazoloxy)propoxy)-2 -ethylchromane-2-carboxylic acid which are potent agonists of peroxisome proliferator activated receptor |
| 03/30/2004 | US6713507 Ether compounds and compositions for cholesterol management and related uses |
| 03/30/2004 | US6713499 Adenosine receptor agonist |